Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Perspectives
Open Access

Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19

Meagan L. Adamsick, Ronak G. Gandhi, Monique R. Bidell, Ramy H. Elshaboury, Roby P. Bhattacharyya, Arthur Y. Kim, Sagar Nigwekar, Eugene P. Rhee and Meghan E. Sise
JASN July 2020, 31 (7) 1384-1386; DOI: https://doi.org/10.1681/ASN.2020050589
Meagan L. Adamsick
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronak G. Gandhi
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monique R. Bidell
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramy H. Elshaboury
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roby P. Bhattacharyya
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roby P. Bhattacharyya
Arthur Y. Kim
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sagar Nigwekar
3Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sagar Nigwekar
Eugene P. Rhee
3Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meghan E. Sise
3Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Mechanism of action of remdesivir. Remdesivir triphosphate leads to delayed chain termination after three additional bases have been added.

Tables

  • Figures
    • View popup
    Table 1.

    Summary of available clinical trial data

    Trial Name/NCT No.Study DesignN, PopulationeGFR CutoffRemdesivir Duration, dOutcomes
    NIAID ACTT-1 studyDouble-blind, placebo-controlled RCT1063 hospitalized adult patients, international3010Interim analysis: median time to recovery 11 versus 15 d; P<0.001; mortality 8% versus 11.6%; P=0.06
    NCT04292899Randomized, open-label trial197 adults with severe COVID-19, international505 versus 1070% clinical recovery and 59% clinical recovery by 14 d in 5- and 10-d groups
    Compassionate use programOpen label, multicenter, nonrandomized>1200 adults, 76 children with COVID-19, international3010Report of 61 treated patients, 8 lost to follow-up; 36 of 53 improved at a median follow-up of 18 d2
    NCT04257656Double-blind, placebo-controlled RCT237 adults with severe COVID-19, China3010No difference in time to clinical improvement; equivalent number of renal AEs in placebo and remdesivir arms3
    • In all cases, remdesivir dosing begins with a 200-mg intravenous loading dose followed by 100 mg intravenously daily. Currently available clinical trial data supporting remdesivir use are shown. NCT, national clinical trial; NIAID ACTT-1, National Institute of Allergy and Infectious Diseases Adaptive Covid-19 Treatment Trial; RCT, randomized, controlled trial; AE, adverse event.

PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 31 (7)
Journal of the American Society of Nephrology
Vol. 31, Issue 7
July 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
Meagan L. Adamsick, Ronak G. Gandhi, Monique R. Bidell, Ramy H. Elshaboury, Roby P. Bhattacharyya, Arthur Y. Kim, Sagar Nigwekar, Eugene P. Rhee, Meghan E. Sise
JASN Jul 2020, 31 (7) 1384-1386; DOI: 10.1681/ASN.2020050589

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
Meagan L. Adamsick, Ronak G. Gandhi, Monique R. Bidell, Ramy H. Elshaboury, Roby P. Bhattacharyya, Arthur Y. Kim, Sagar Nigwekar, Eugene P. Rhee, Meghan E. Sise
JASN Jul 2020, 31 (7) 1384-1386; DOI: 10.1681/ASN.2020050589
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Remdesivir
    • Risks of Remdesivir
    • Risk of SBECD Carrier Accumulation
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Separate and Unequal: Race-Based Algorithms and Implications for Nephrology
  • COVID-19 and Dialysis Patients: Unsolved Problems in Early 2021
  • Ensuring the Equitable Advancement of American Kidney Health—the Need to Account for Socioeconomic Disparities in the ESRD Treatment Choices Model
Show more Perspectives

Cited By...

  • New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
  • Management of COVID-19 in special populations with kidney disease
  • Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
  • Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
  • Google Scholar

Similar Articles

Related Articles

  • Remdesivir in COVID-19 Patients with Impaired Renal Function
  • Authors’ Reply
  • PubMed
  • Google Scholar

Keywords

  • acute renal failure
  • end-stage renal disease
  • antiviral
  • COVID-19

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire